Hi, sir, thank you for taking my question. I wanted to understand more about the consumer health segment. How are you thinking in terms of increasing the expense from here basis the kind of traction that you are seeing?
So, do we expect the spend to be at similar level or can it go up significantly from here?
Congratulations on a good set of numbers. My first question is regarding the Nagpur facility. So we have seen a new competitor entered the market. Do we see any kind of competitive pressure in terms of doctor hiring? And you also announced that you were -- you might be looking to expand in Nagpur region. So any sense what is happening from a competition perspective on that locality?
Sir, my next question is on the insurance that you did mention about insurance being a significant growth driver in your opening comments with some regulation changes. I just wanted to understand that if we think of it from a metro city versus a Tier 2 and beyond approach, I think in the past, you have highlighted that insurance is more of a Tier 1 and metro city phenomenon. But if you put it in terms of your growth drivers, do you see insurance of significant growth drivers specifically for the Tier 2 and beyond?
My question was on the cost line. So this quarter, we have seen significant reduction in the other expenses. So I wanted to understand what drove this reduction and can we see this as a sustainable...
Yes. Cost reduction in 3Q versus the previous quarter?
Hi, thank you for taking my question. My question is regarding the Hyderabad region. So, we have already reached around a thousand beds in the region. So, I wanted to understand what is the kind of headroom you see for Rainbow in that region, and how do you determine how much capacity the region can hold?
I got it. Thank you, sir. That was my only question.
So sir, continuing on the lines of the previous question regarding the GLP-1 products, sir, could you give more color on the timeline that we can look for this product? Would it be FY '26 opportunity or would it come even later? And what stage are we doing -- are we already -- can we exhibit batches to customer or where to we lag in terms of progress over there?
Sir, this quarter, we also saw an increase in sales for the carotenoid products by around 15%. And given the carotenoid were already at 90%, 95% capacity, would this be more price driven or is there something else that is going there?